A Phase 2b Study of KW-6356 in Subjects With Parkinson's Disease on Treatment With Levodopa-containing Preparations
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2019
At a glance
- Drugs KW 6356 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Kyowa Hakko Kirin
- 18 Sep 2018 Status changed from planning to recruiting.
- 04 Sep 2018 New trial record
- 20 Aug 2018 According to a Kyowa Hakko Kirin media release, the company plans to initiate this late phase 2 clinical trial of KW-6356 for Parkinsons disease patients in Japan by the end of 2018.